Linezolid Accord

Linezolid, the active ingredient in Linezolid Accord, is an oxazolidinone presented as an intravenous formulation for use in hospitalized patients. It treats serious Gram‑positive bacterial infections such as skin and soft‑tissue infections, community‑acquired and nosocomial pneumonia, and infections caused by methicillin‑resistant Staphylococcus aureus (MRSA).

GNH USA supplies Linezolid Accord as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinical centres worldwide, including tertiary care and specialty units, ensuring reliable access for infection management programs.

Linezolid is an oxazolidinone antibiotic indicated for infections caused by Gram‑positive bacteria. - Gram‑positive bacterial infections: Effective against severe infections caused by susceptible Gram‑positive organisms. - Skin and soft tissue infections: Treats cellulitis, abscesses and other soft‑tissue infections. - Community‑acquired and nosocomial pneumonia: Used for serious lung infections, including hospital‑acquired cases. - MRSA infections: Provides activity against methicillin‑resistant Staphylococcus aureus strains.

Linezolid may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: feeling of sickness or urge to vomit. - Diarrhea: loose, frequent stools. - Headache: mild to moderate head pain.

Serious or Rare Side Effects: - Thrombocytopenia: significant drop in platelet count, increasing bleeding risk. - Serotonin syndrome: potentially life‑threatening condition when combined with serotonergic agents. - Peripheral neuropathy: nerve damage causing numbness or tingling.

When using Linezolid, several safety considerations should be observed. - Renal impairment: monitor renal function and adjust therapy as needed. - Hepatic dysfunction: assess liver enzymes regularly during treatment. - Concomitant serotonergic drugs: avoid use due to risk of serotonin syndrome. - Prolonged therapy (>14 days): perform periodic blood count monitoring. - Hypersensitivity reactions: discontinue immediately if rash, itching, or anaphylaxis occurs. - Store at ambient temperature: keep in original container, protect from moisture and light.

Linezolid can interact with other medicines, requiring attention to avoid adverse effects.

Major Interactions (Avoid): - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): risk of serotonin syndrome. - Monoamine oxidase inhibitors (MAOIs): increased serotonin toxicity. - Rifampicin: induces metabolism, reducing linezolid exposure.

Moderate Interactions (Monitor Closely): - Warfarin: may potentiate anticoagulant effect, monitor INR. - NSAIDs: increased risk of bleeding when combined with thrombocytopenia. - Anticonvulsants (e.g., carbamazepine, phenytoin): may affect blood counts; monitor hematology.